/
NUWE
$3.18-$0.12 (-3.64%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.2M
0M shares
52-week range
$2.88 – $908.25
0% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
48.37%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-21145946.82
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M | $5.5M | $7.4M | $7.9M | $8.5M | $8.9M | $8.7M | $8.3M |
| Cost of revenue | $3.7M | $2.7M | $3.4M | $3.4M | $3.8M | $3.9M | $2.9M | $3.1M |
| Gross profit | $1.3M | $2.9M | $4.1M | $4.5M | $4.8M | $5.0M | $5.8M | $5.1M |
| Gross margin | 26.6% | 51.7% | 54.5% | 56.7% | 55.7% | 56.2% | 66.7% | 62.0% |
| R&D | $3.1M | $4.7M | $3.7M | $5.0M | $4.3M | $5.4M | $3.2M | $2.7M |
| Operating income | −$17.0M | −$18.1M | −$17.0M | −$19.5M | −$17.2M | −$17.6M | −$11.0M | −$11.1M |
| EBITDA | −$16.8M | −$17.9M | −$16.7M | −$19.1M | −$4.9M | −$16.4M | −$10.5M | −$6.5M |
| Net income | −$17.0M | −$18.1M | −$15.8M | −$19.6M | −$14.5M | −$20.2M | −$11.2M | −$17.5M |
| Net margin | -340.8% | -328.7% | -212.8% | -246.9% | -170.0% | -228.0% | -127.7% | -211.9% |
| EPS (diluted) | -149030000.00 | -14408863.70 | -709679.95 | -350143.15 | -102268.25 | -12602.45 | -280.00 | -25.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-80.15 | $-80.15–$-80.15 | 1 |
| 2027 | $11M | $-22.05 | $-22.05–$-22.05 | 1 |
| 2028 | $36M | $1043.70 | $1043.70–$1043.70 | 1 |
| 2029 | $49M | $2087.40 | $2087.40–$2087.40 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.55
Price
$3.18
Implied downside
-83%
Peer comparison
Nuwellis, Inc. Common Stock
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
www.nuwellis.com- Employees
- 38
- IPO / List date
- Feb 16, 2012
- HQ
- EDEN PRAIRIE, MN
Held by traders on TradeandTell
No one on the platform currently holds NUWE.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in NUWE as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-26 | 1-for-35reverse |
| 2025-07-07 | 1-for-42reverse |
| 2024-06-28 | 1-for-35reverse |
| 2022-12-12 | 1-for-100reverse |
| 2020-10-19 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded NUWE yet.
